Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Clobenzorex is a central nervous system stimulant and anorectic drug, chemically classified as an N-substituted amphetamine and phenethylamine. It acts as a prodrug of amphetamine, being metabolized in the body to amphetamine and other metabolites such as 4-hydroxyclobenzorex. Its primary clinical use is as an appetite suppressant for the management of obesity. The drug exerts its effects by stimulating the release of norepinephrine and dopamine in the brain, leading to reduced appetite and increased satiety. Clobenzorex has been marketed under several brand names, including Asenlix, primarily in Mexico and parts of Latin America. It is supplied typically as hydrochloride salt in oral capsules[1][2][3][6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on clobenzorex.